Alder Biopharmaceuticals (NASDAQ:ALDR) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.23, Briefing.com reports. The business had revenue of $0.94 million for the quarter. During the same quarter in the previous year, the company earned ($0.97) EPS.
Alder Biopharmaceuticals (NASDAQ ALDR) opened at $14.20 on Wednesday. Alder Biopharmaceuticals has a 12-month low of $8.60 and a 12-month high of $24.65.
ALDR has been the subject of a number of research analyst reports. Mizuho reiterated a “buy” rating and issued a $32.00 price target on shares of Alder Biopharmaceuticals in a report on Wednesday, November 8th. BidaskClub downgraded Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 19th. BMO Capital Markets reiterated a “buy” rating and issued a $22.00 price target on shares of Alder Biopharmaceuticals in a report on Wednesday, January 3rd. ValuEngine upgraded Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Finally, Zacks Investment Research downgraded Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. Four analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $28.14.
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.